Skip to main content
Medic Debate
- The Antidote to Medical Misinformation and Propaganda!
Languages
Dansk
Nederlands
English
Français
Deutsch
Italiano
Español
Kiswahili
Svenska
Search form
Search
Main menu
Home
Search
About us
Books
Category Search
Log In
Recent posts
Treatment Protocols
You are here
Home
Gemcitabine
Items per page
5
10
20
40
60
100
Title
Average Rating
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growt
80.00%
Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced
90.00%
Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma.
70.00%
Phase I trial of capecitabine (Cap) and gemcitabine (G) with concurrent radical radiotherapy in locally advanced pancreatic ca..
40.00%
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors.
70.00%
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp
60.00%
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting".
60.00%
Gemcitabine
Final analysis of a multicenter, randomized phase II trial comparing three different chemoradiotherapy regimens in the treatment
30.00%
Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual sta
80.00%
Effect of emodin combined gemcitabine on the growth and apoptosis of pancreatic cancer cell line BxPC-3 in vitro
80.00%
Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?
50.00%
Dendritic cell-based vaccination in combination with gemcitabine/S-1 in patients with advanced pancreatic cancer. Sub-category:
90.00%
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.
70.00%
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer.
50.00%
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients wi
60.00%
71 year old woman, Pancraetic cancer with liver and lung metastasis.
90.00%
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and m
60.00%
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model.
70.00%
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer.
40.00%